Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease

BACKGROUND: Bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease — one...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Salloway, Stephen, Sperling, Reisa, Fox, Nick C., Blennow, Kaj, Klunk, William, Raskind, Murray, Sabbagh, Marwan, Honig, Lawrence S., Porsteinsson, Anton P., Ferris, Steven, Reichert, Marcel, Ketter, Nzeera, Nejadnik, Bijan, Guenzler, Volkmar, Miloslavsky, Maja, Wang, Daniel, Lu, Yuan, Lull, Julia, Tudor, Iulia Cristina, Liu, Enchi, Grundman, Michael, Yuen, Eric, Black, Ronald, Brashear, H. Robert
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4159618/
https://ncbi.nlm.nih.gov/pubmed/24450891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1304839
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars